PH12020551805A1 - Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof - Google Patents

Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof

Info

Publication number
PH12020551805A1
PH12020551805A1 PH12020551805A PH12020551805A PH12020551805A1 PH 12020551805 A1 PH12020551805 A1 PH 12020551805A1 PH 12020551805 A PH12020551805 A PH 12020551805A PH 12020551805 A PH12020551805 A PH 12020551805A PH 12020551805 A1 PH12020551805 A1 PH 12020551805A1
Authority
PH
Philippines
Prior art keywords
binding proteins
receptor type
cannabinoid receptor
binding
engineered
Prior art date
Application number
PH12020551805A
Other languages
English (en)
Inventor
Antara Banerjee
Andrea Fanjul
Robert J Hoey
Kacey Sachen
Nikolai Suslov
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PH12020551805A1 publication Critical patent/PH12020551805A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PH12020551805A 2018-04-30 2020-10-29 Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof PH12020551805A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30
PCT/IB2019/000503 WO2019211665A1 (en) 2018-04-30 2019-04-29 Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
PH12020551805A1 true PH12020551805A1 (en) 2021-07-26

Family

ID=67396963

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551805A PH12020551805A1 (en) 2018-04-30 2020-10-29 Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof

Country Status (21)

Country Link
US (3) US12202901B2 (https=)
EP (1) EP3787746A1 (https=)
JP (2) JP7431750B2 (https=)
KR (1) KR20210005051A (https=)
CN (1) CN112218684A (https=)
AR (1) AR114436A1 (https=)
AU (1) AU2019264029A1 (https=)
BR (1) BR112020022035A2 (https=)
CA (1) CA3098416A1 (https=)
CL (1) CL2020002793A1 (https=)
CO (1) CO2020014681A2 (https=)
EA (1) EA202092593A1 (https=)
EC (1) ECSP20076576A (https=)
IL (1) IL278276B1 (https=)
MA (1) MA52504A (https=)
MX (1) MX2020011498A (https=)
PE (1) PE20210419A1 (https=)
PH (1) PH12020551805A1 (https=)
SG (1) SG11202010388SA (https=)
TW (1) TWI882957B (https=)
WO (1) WO2019211665A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098416A1 (en) 2018-04-30 2019-11-07 Takeda Pharmaceutical Company Limited Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
EP4504792A4 (en) * 2022-04-04 2026-04-15 Bird Rock Bio Sub Inc PREDICTION AND TREATMENT OF RAPIDLY PROGRESS KIDNEY DISEASE
JPWO2023234406A1 (https=) 2022-06-03 2023-12-07
WO2023242843A1 (en) * 2022-06-17 2023-12-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2025257151A1 (en) * 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
AU2014302410B2 (en) 2013-06-26 2019-06-13 Amgen Inc. CB1 receptor antigen-binding proteins and uses thereof
MA39708A (fr) 2014-03-27 2021-03-31 Bird Rock Bio Inc Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
BR112018006633A2 (en) * 2015-09-30 2018-10-23 Bird Rock Bio, Inc. antibodies that bind to human cannabinoid receptor 1 (cb1)
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
CA3098416A1 (en) 2018-04-30 2019-11-07 Takeda Pharmaceutical Company Limited Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof

Also Published As

Publication number Publication date
CN112218684A (zh) 2021-01-12
WO2019211665A1 (en) 2019-11-07
AU2019264029A1 (en) 2020-11-19
US20250250341A1 (en) 2025-08-07
JP2024059646A (ja) 2024-05-01
US11746155B2 (en) 2023-09-05
TWI882957B (zh) 2025-05-11
MX2020011498A (es) 2021-01-29
IL278276B1 (en) 2026-02-01
AR114436A1 (es) 2020-09-02
PE20210419A1 (es) 2021-03-08
MA52504A (fr) 2021-04-28
US12202901B2 (en) 2025-01-21
JP2021525059A (ja) 2021-09-24
JP7431750B2 (ja) 2024-02-15
EP3787746A1 (en) 2021-03-10
ECSP20076576A (es) 2021-12-30
US20210198358A1 (en) 2021-07-01
CL2020002793A1 (es) 2021-02-12
TW202003549A (zh) 2020-01-16
SG11202010388SA (en) 2020-11-27
US20220396620A1 (en) 2022-12-15
BR112020022035A2 (pt) 2021-02-02
CA3098416A1 (en) 2019-11-07
IL278276A (https=) 2020-12-31
EA202092593A1 (ru) 2021-02-12
JP7798931B2 (ja) 2026-01-14
KR20210005051A (ko) 2021-01-13
CO2020014681A2 (es) 2020-12-10

Similar Documents

Publication Publication Date Title
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
PH12019502356A1 (en) Trem2 antigen binding proteins and uses thereof
MY187975A (en) Antigen-binding proteins that activate the leptin receptor
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
WO2020121195A8 (en) Trem2 antibodies and uses thereof
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
MX2025000260A (es) Proteina de union al antigeno anti-steap1
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12019502763A1 (en) Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
MY185813A (en) Factor xi antibodies and methods of use
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
NZ599875A (en) Human il-23 antigen binding proteins
WO2018069871A3 (en) Anti-kras binding proteins
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
WO2020128446A3 (en) Anti-btla antibodies
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
EP4613772A3 (en) Antigen-binding proteins that antagonize leptin receptor
MX2022001604A (es) Anticuerpos anti bdca-2.
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof